Compare OMC & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMC | WST |
|---|---|---|
| Founded | 1944 | 1923 |
| Country | United States | United States |
| Employees | 74900 | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | OMC | WST |
|---|---|---|
| Price | $79.97 | $274.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $93.33 | ★ $345.75 |
| AVG Volume (30 Days) | ★ 6.2M | 691.8K |
| Earning Date | 02-03-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.00% | 0.32% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | ★ 6.79 | 6.75 |
| Revenue | ★ $16,065,300,000.00 | $3,017,900,000.00 |
| Revenue This Year | $4.67 | $7.01 |
| Revenue Next Year | $23.36 | $6.20 |
| P/E Ratio | ★ $11.79 | $40.63 |
| Revenue Growth | 4.13 | ★ 4.92 |
| 52 Week Low | $68.37 | $187.43 |
| 52 Week High | $89.35 | $348.90 |
| Indicator | OMC | WST |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 51.83 |
| Support Level | $78.11 | $264.92 |
| Resistance Level | $81.88 | $279.01 |
| Average True Range (ATR) | 1.84 | 6.69 |
| MACD | 0.21 | 0.60 |
| Stochastic Oscillator | 68.96 | 61.67 |
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.